Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenstrom's Macroglobulinemia

被引：11

作者：

Garcia-Sanz, R. ^{[1
,2
]}

Ocio, E. M. ^{[1
,2
]}

del Carpio, D. ^{[1
]}

Caballero, A. ^{[1
]}

Magalhaes, R. J. P. ^{[1
]}

Alonso, J. ^{[1
]}

Lopez-Anglada, L. ^{[1
]}

Villaescusa, T. ^{[1
]}

Puig, N. ^{[1
]}

Hernandez, J. M. ^{[3
]}

Fernandez-Calvo, J. ^{[3
]}

Aguilar, A. ^{[3
]}

Martin, A. ^{[3
]}

Lopez, R. ^{[3
]}

Paiva, B.

Orfao, A. ^{[2
]}

Vidriales, B. ^{[1
]}

San-Miguel, J. F. ^{[1
,2
]}

机构：

[1] Univ Salamanca, Hosp Univ Salamanca, E-37008 Salamanca, Spain

[2] Univ Salamanca, Ctr Invest Canc, E-37008 Salamanca, Spain

[3] Univ Salamanca, Castellano Leones Spain Study Grp Study Monoclona, E-37008 Salamanca, Spain

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2011年 / 11卷 / 01期

关键词：

CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP; MYELOMA PATIENTS; RITUXIMAB;

D O I：

10.3816/CLML.2011.n.040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To assess the value of bone marrow (BM) assessment by flow cytometry FCM after therapy in the clinical outcome of WM patients, we analyzed 42 WM patients who were evaluated before and after therapy. Patients were studied with a panel that always included the CD 19, CD22, CD25, and kappa/lambda light chain immunoglobulin monoclonal antibodies. The mean of abnormal B-cells in the pre-therapeutic BM was 17.8% +/- 12.1%, which decreased was after therapy to 5.4% +/- 0.7% (P = .049). A linear correlation was seen between the better quality of response and the reduction in the tumor B-lymphocyte counts at the BM, since the ratio of abnormal B cells between pre and posttherapy BM was 1172.17, 221.64, 3.37, 1.03, and 0.56 for responses complete, partial, minor, stable disease and progression, respectively (P < .001). Intensive and rituximab-containing therapies correlated with deeper tumor cell reductions. Finally, the B-cell decrease correlated with the better overall and progression-free survival.

引用

页码：168 / 171

页数：4

共 16 条

[1] Waldenstrom macroglobulinaemia:: presenting features and outcome in a series with 217 cases [J].

García-Sanz, R ;

Montoto, S ;

Torrequebrada, A ;

de Coca, AG ;

Petit, J ;

Sureda, A ;

Rodríguez-García, JA ;

Massó, P ;

Pérez-Aliaga, A ;

Monteagudo, MD ;

Navarro, I ;

Moreno, G ;

Toledo, C ;

Alonso, A ;

Besses, C ;

Besalduch, J ;

Jarque, I ;

Salama, P ;

Rivas, JAH ;

Navarro, B ;

Bladé, J ;

Miguel, JFS .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :575-582

[2] Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waidenstrom's macroglobulinemia [J].

Gertz, MA ;

Anagnostopoulos, A ;

Anderson, K ;

Branagan, AR ;

Coleman, M ;

Frankel, SR ;

Giralt, S ;

Levine, T ;

Munshi, N ;

Pestronk, A ;

Rajkumar, V ;

Treon, SP .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :121-126

[3] Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial [J].

Gertz, Morie A. ;

Abonour, Rafat ;

Heffner, Leonard T. ;

Greipp, Philip R. ;

Uno, Hajime ;

Rajkumar, S. V. .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (05) :677-680

[4] Initial immunoglobulin M 'Flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia an eastern cooperative oncology group study [J].

Ghobrial, IM ;

Fonseca, R ;

Greipp, PR ;

Blood, E ;

Rue, M ;

Vesole, DH ;

Gertz, MA .

CANCER, 2004, 101 (11) :2593-2598

[5] Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia [J].

Kimby, Eva ;

Treon, Steven P. ;

Anagnostopoulos, Athanasios ;

Dimopoulos, Meletios ;

Garcia-Sanz, Ramon ;

Gertz, Morie A. ;

Johnson, Stephen ;

LeBlond, Veronique ;

Fermand, Jean-Paul ;

Maloney, David G. ;

Merlini, Giampaolo ;

Morel, Pierre ;

Morra, Enrica ;

Nichols, Gwen ;

Ocio, Enrique M. ;

Owen, Roger ;

Stone, Marvin ;

Blade, Joan .

CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05) :380-383

[6]

LELEU X, 2008, LEUKEMIA LYMPHOMA, P1

[7] Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation [J].

Paiva, Bruno ;

Vidriales, Maria-Belen ;

Cervero, Jorge ;

Mateo, Gema ;

Perez, Jose J. ;

Montalban, Maria A. ;

Sureda, Anna ;

Montejano, Laura ;

Gutierrez, Norma C. ;

de Coca, Alfonso Garcia ;

Heras, Natalia de las ;

Mateos, Maria V. ;

Lopez-Berges, Maria C. ;

Garcia-Boyero, Raimundo ;

Galende, Josefina ;

Hernandez, Jose ;

Palomera, Luis ;

Carrera, Dolores ;

Martinez, Rafael ;

de la Rubia, Javier ;

Martin, Alejandro ;

Blade, Joan ;

Lahuerta, Juan J. ;

Orfao, Alberto ;

Miguel, Jesus F. San .

BLOOD, 2008, 112 (10) :4017-4023

[8] Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients [J].

Paiva, Bruno ;

Vidriales, Maria-Belen ;

Perez, Jose J. ;

Mateo, Gema ;

Montalban, Maria Angeles ;

Mateos, Maria Victoria ;

Blade, Joan ;

Lahuerta, Juan Jose ;

Orfao, Alberto ;

San Miguel, Jesus F. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (11) :1599-1602

[9] International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia [J].

Rawstron, A. C. ;

Villamor, N. ;

Ritgen, M. ;

Boettcher, S. ;

Ghia, P. ;

Zehnder, J. L. ;

Lozanski, G. ;

Colomer, D. ;

Moreno, C. ;

Geuna, M. ;

Evans, P. A. S. ;

Natkunam, Y. ;

Coutre, S. E. ;

Avery, E. D. ;

Rassenti, L. Z. ;

Kipps, T. J. ;

Caligaris-Cappio, F. ;

Kneba, M. ;

Byrd, J. C. ;

Hallek, M. J. ;

Montserrat, E. ;

Hillmen, P. .

LEUKEMIA, 2007, 21 (05) :956-964

[10] Immunophenotypic analysis of Waldenstrom's macroglobulinemia [J].

San Miguel, JF ;

Vidriales, MB ;

Ocio, E ;

Mateo, G ;

Sánchez-Guijo, F ;

Sánchez, ML ;

Escribano, L ;

Bárez, A ;

Moro, MJ ;

Hernández, J ;

Aguilera, C ;

Cuello, R ;

García-Frade, J ;

López, R ;

Portero, J ;

Orfao, A .

SEMINARS IN ONCOLOGY, 2003, 30 (02) :187-195

← 1 2 →

Post-Treatment Bone Marrow Residual Disease &gt; 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenstrom's Macroglobulinemia

Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenstrom's Macroglobulinemia